Merit Medical to Present at the 2024 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Congress
Merit Medical Systems (NASDAQ: MMSI) announced its participation in the 2024 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Congress in Lisbon, Portugal. The company will present updates on two pivotal studies:
1. 6-month clinical outcomes from the WAVE study during the FIRST@CIRSE Clinical Trial session.
2. An overview of the MOTION study design and methodology during the News on Stage session.
Merit will also sponsor two symposia focusing on:
- Clinical management of synovial arterial hypervascularity in the knee (September 15)
- Maintaining long-term patency for hemodialysis patients (September 16)
These sessions can be viewed with a free myCIRSE account, with on-demand access available within 24 hours after the live sessions.
Merit Medical Systems (NASDAQ: MMSI) ha annunciato la sua partecipazione al Congresso Annuale della Società Europea di Radiologia Cardiovascolare e Interventistica (CIRSE) 2024 a Lisbona, Portogallo. L'azienda presenterà aggiornamenti su due studi fondamentali:
1. Esiti clinici di 6 mesi dallo studio WAVE durante la sessione Clinical Trial FIRST@CIRSE.
2. Un panorama del disegno e della metodologia dello studio MOTION durante la sessione News on Stage.
Merit sponsorizzerà anche due simposi focalizzati su:
- Gestione clinica dell'ipervascularità arteriosa sinoviale nel ginocchio (15 settembre)
- Mantenimento della patenza a lungo termine per i pazienti in emodialisi (16 settembre)
Queste sessioni sono accessibili con un conto myCIRSE gratuito, con accesso on-demand disponibile entro 24 ore dopo le sessioni dal vivo.
Merit Medical Systems (NASDAQ: MMSI) anunció su participación en el Congreso Anual de la Sociedad Europea de Radiología Cardiovascular e Intervencionista (CIRSE) 2024 en Lisboa, Portugal. La compañía presentará actualizaciones sobre dos estudios clave:
1. Resultados clínicos a 6 meses del estudio WAVE durante la sesión Clinical Trial FIRST@CIRSE.
2. Una visión general del diseño y la metodología del estudio MOTION durante la sesión News on Stage.
Merit también patrocinará dos simposios centrados en:
- Gestión clínica de la hipervascularidad arterial sinovial en la rodilla (15 de septiembre)
- Mantenimiento de la permeabilidad a largo plazo para pacientes en hemodiálisis (16 de septiembre)
Estas sesiones se pueden ver con una cuenta gratuita de myCIRSE, con acceso bajo demanda disponible dentro de las 24 horas posteriores a las sesiones en vivo.
Merit Medical Systems (NASDAQ: MMSI)는 포르투갈 리스본에서 열리는 2024 유럽 심혈관 개입 방사선학회(CIRSE) 연례 총회에 참여한다고 발표했습니다. 이 회사는 두 가지 중요한 연구에 대한 업데이트를 발표할 예정입니다:
1. FIRST@CIRSE 임상 시험 세션에서 WAVE 연구의 6개월 임상 결과.
2. News on Stage 세션에서 MOTION 연구 설계 및 방법론에 대한 개요.
Merit는 또한 다음을 주제로 두 개의 심포지엄을 후원합니다:
- 무릎의 시노비아 혈관의 임상 관리 (9월 15일)
- 혈액 투석 환자를 위한 장기적 개통 유지 (9월 16일)
이 세션은 무료 myCIRSE 계정을 통해 시청할 수 있으며, 라이브 세션 후 24시간 이내에 온디맨드 접근이 가능합니다.
Merit Medical Systems (NASDAQ: MMSI) a annoncé sa participation au Congrès Annuel de la Société Européenne de Radiologie Cardiovasculaire et Interventionnelle (CIRSE) 2024 à Lisbonne, Portugal. L'entreprise présentera des mises à jour sur deux études clés :
1. Résultats cliniques à 6 mois de l'étude WAVE lors de la session Clinical Trial FIRST@CIRSE.
2. Un aperçu du design et de la méthodologie de l'étude MOTION durant la session News on Stage.
Merit parrainera également deux symposiums axés sur :
- Gestion clinique de l’hypervascularité artérielle synoviale au genou (15 septembre)
- Maintien de la perméabilité à long terme pour les patients sous hémodialyse (16 septembre)
Ces sessions peuvent être visionnées avec un compte myCIRSE gratuit, avec accès à la demande disponible dans les 24 heures suivant les sessions en direct.
Merit Medical Systems (NASDAQ: MMSI) kündigte seine Teilnahme am Jahreskongress der Europäischen Gesellschaft für Herz-Kreislauf- und Interventionale Radiologie (CIRSE) 2024 in Lissabon, Portugal, an. Das Unternehmen wird Updates zu zwei entscheidenden Studien präsentieren:
1. 6-Monats klinische Ergebnisse aus der WAVE-Studie während der FIRST@CIRSE Clinical Trial-Sitzung.
2. Einen Überblick über das Studiendesign und die Methodologie der MOTION-Studie während der News on Stage-Sitzung.
Merit wird auch zwei Symposien sponsern, die sich auf Folgendes konzentrieren:
- Klinisches Management der synovialen arteriellen Hypervaskularität am Knie (15. September)
- Langfristige Offenhaltung für Hämodialysepatienten (16. September)
Diese Sitzungen können mit einem kostenlosen myCIRSE-Konto angesehen werden, wobei der On-Demand-Zugriff innerhalb von 24 Stunden nach den Live-Sitzungen verfügbar ist.
- None.
- None.
SOUTH JORDAN, Utah, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that clinicians will present updates on two of its pivotal studies during scientific sessions held on September 14 at CIRSE in Lisbon, Portugal.
Data will include 6-month clinical outcomes from the WAVE study, presented during the FIRST@CIRSE Clinical Trial session held between 11:30 and 12:30. An overview of the MOTION study design and methodology will be presented during the News on Stage session, “Meet the Brains Behind These Landmark Trials,” held between 13:00 and 14:00.
In addition to presenting at scientific sessions, Merit will sponsor two symposia. On September 15, from 11:30 to 12:30 in Auditorium 2, the satellite symposium will focus on current evidence and strategies for the clinical management of treating synovial arterial hypervascularity in the knee. On September 16, from 13:00 to 14:00 in Auditorium 7, the symposium will center on clinical evidence and treatment strategies to maintain long-term patency for patients undergoing hemodialysis.
“We are honored to attend CIRSE, connect with our physician partners, and all interventional radiologists who will attend the conference,” said Fred Lampropoulos, Merit’s Chairman and Chief Executive Officer.
Symposia can be viewed with a free myCIRSE account; no registration is required. On-demand access to sponsored sessions will be available within the first 24 hours after the live session is over and can be viewed with a free myCIRSE account; no registration is required. To create a myCIRSE account, visit https://login.cirse.org/login
ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 700 individuals. Merit employs approximately 7,100 people worldwide.
TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.
CONTACTS
PR/Media Inquiries
Sarah Comstock
Merit Medical
+1-801-432-2864 | sarah.comstock@merit.com
INVESTOR INQUIRIES
Mike Piccinino, CFA, IRC
Westwicke - ICR
+1-443-213-0509 | mike.piccinino@westwicke.com
FAQ
What studies will Merit Medical present at CIRSE 2024?
When and where will Merit Medical's CIRSE 2024 presentations take place?
What topics will Merit Medical's sponsored symposia cover at CIRSE 2024?
How can attendees access Merit Medical's sponsored sessions at CIRSE 2024?
What is Merit Medical Systems' stock symbol?
